About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 137304, 10 pages
http://dx.doi.org/10.1155/2014/137304
Research Article

Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

1Department of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Straße 65, 93053 Regensburg, Germany
2Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany
3Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany
4Tumor Center Regensburg e.V., University of Regensburg, 93053 Regensburg, Germany

Received 10 January 2014; Accepted 6 February 2014; Published 20 March 2014

Academic Editor: Peter A. Fasching

Copyright © 2014 E. C. Inwald et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

E. C. Inwald, O. Ortmann, F. Zeman, et al., “Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry,” BioMed Research International, vol. 2014, Article ID 137304, 10 pages, 2014. doi:10.1155/2014/137304